Enzene launches NeX model to cut biologics facility build costs by up to 80%
Built on the EnzeneX continuous manufacturing platform, NeX targets facility delivery for $60-80m versus conventional $300-400m fed-batch builds, offering governments and biopharma organisations commercial-ready biomanufacturing in under three years